Skip to main content
OpenTrials
Completed

NCT Number: NCT01851564

RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage

The mortality rates from Acute Variceal Haemorrhage remain significant and first line therapy may fail in 15-25% of patients. The self-expandable metal stent has been described in case series as having a very high efficacy at control of haemorrhage from oesophageal varices when used as rescue therapy. This randomised controlled trial aims to assess for any potential superiority of the stent over 'standard' endoscopic techniques as primary or rescue therapy for bleeding oesophageal varices.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

United Bristol Hospitals NHS Foundation Trust, Bristol, United Kingdom

Loading trial locations.

About this study

Despite improvements in recent years, mortality from variceal bleeding remains significant. The routine use of banding ligation, vasoactive drugs, and antibiotics has had an impact on survival rates such that survival rates of patients with Childs-Pugh A and B class cirrhosis may be as high as 90% at 30 days. However, the successful outcome of variceal bleeding is compromised in some patients because of initial failure to control bleeding or early re-bleeding, both of which have a significant impact on mortality.

The SX-Ella Danis stent (Ella-CS, Hradec Kralove, Czech Republic) is a removable, covered, self-expanding mesh-metal stent (SEMS) that can be deployed in the lower oesophagus over an endoscopically placed guidewire without radiological screening. The stent controls bleeding by tamponade of varices in the lower oesophagus.

The series reported to date suggest that the self-expandable covered stents can provide 100% haemostasis rates when applied for refractory oesophageal variceal bleeding. Given the potentially lower risks of re-bleeding and safe, easy insertion techniques the self-expandable covered stents may offer a superior alternative to standard endoscopic therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Arm 1: Participants with Child-Pugh grade B or C cirrhosis with variceal haemorrhage, where the bleeding is from a site which would ordinarily be treated with band ligation . The diagnosis of cirrhosis may be proven by previous histology or suspected using clinical, radiological and biochemical data.
  • Arm 2: Participants with Child-Pugh grade A, B or C cirrhosis who present with failure to control bleeding within 5 days of an initial attempt at standard endoscopic therapy of acute haemorrhage from a site which would ordinarily be treated with band ligation.

Exclusion criteria

  • < 18 Years of age
  • Child-Pugh grade A cirrhosis (for Arm 1 only)
  • Varices which would not be treated with band ligation as standard therapy
  • Non-cirrhotic portal hypertension
  • Malignancy of the oesophagus, stomach or upper respiratory tract
  • Oesophageal stenosis which prohibits endoscopy
  • Recent oesophageal surgery
  • A large hiatus hernia which prevents stent placement
  • Known hepatocellular carcinoma considered to be incurable (according to Milan Criteria)
  • Patients in the terminal phases of hepatological or other disease
  • Pregnancy

Treatment and study plan

Self-expanding mesh-metal oesophageal stent (SEMS)

Device

A removable stent designed for the treatment of bleeding oesophageal varices.

Other names: DANIS Stent

Standard therapy

Other

Standard Medical and Endoscopic Therapy

Primary outcomes

  1. Failure to Control Bleeding

    Time frame: 7 days

    Failure to control Bleeding (as defined by the Baveno V Criteria) or re-bleeding within 7 days.

Secondary outcomes

  1. Absence of Bleeding at 14 and 42 days

    Time frame: 14 and 42 days

  2. Participant Survival

    Time frame: 7, 14, 42 days and 6 months

  3. Absence of Stent Migration

    Time frame: 7 days

    for the duration of stent migration

  4. Requirement for Blood products

    Time frame: 7 days

  5. Requirement for Analgesia and Sedation whilst Stent in in situ

    Time frame: 7 days

  6. Presence of Thoracic Pain or Dysphagia

    Time frame: 7 days

  7. Length of Intensive Care Unit and Total Hospital Stay

    Time frame: Total Length of Intensive Care Unit and Hospital Stay (an average of 3 and 10 days respectively)

  8. Requirement for additional endoscopic therapy or salvage therapy (such as TIPS)

    Time frame: 7 days

  9. Repeated presentation with variceal bleeding within 6 months

    Time frame: 6 months

Other outcomes

  1. Unexpected Serious Adverse Device Effect

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University College, London

Other

Collaborators

  • Barts & The London NHS Trust
  • Royal Free Hampstead NHS Trust
  • University Hospitals Bristol and Weston NHS Foundation Trust

Registry information

Official study title

Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study.

Acronym: SOV

Important dates

Study start
2012
Primary completion
2015
Study completion
2016
First posted
May 10, 2013
Registry last updated
Sep 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.